Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Curr Probl Dermatol. 2009;38:107-36. doi: 10.1159/000232307. Epub 2009 Jul 28.

Management of severe psoriasis with TNF antagonists. Adalimumab, etanercept and infliximab.

Author information

  • 1Department of Dermatology, Georg August University, Gottingen, Germany. rmoess@gwdg.de

Abstract

Three specific tumor necrosis factor (TNF) antagonists, adalimumab, etanercept and infliximab, have been approved for the treatment of psoriasis. Their efficacy, not only in psoriasis but also in psoriatic arthritis, has been demonstrated in large prospective randomized placebo-controlled trials. At present, the discussion about the use of these drugs is dominated by issues of the risk-benefit ratio and by economic considerations. In this chapter, we give an introduction to the different TNF antagonists, with the main focus on therapy management and safety issues.

Copyright (c) 038\ S. Karger AG, Basel.

PMID:
19710553
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Loading ...
    Write to the Help Desk